Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2020-07-10 Regulatory Filings
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience Plc - Atox Bio plans NDA submission for Q3 2020
Regulatory Filings Classification · 1% confidence The document is an announcement by Arix Bioscience plc regarding the positive results from its portfolio company Atox Bio's Phase 3 clinical trial (ACCUTE trial) for the drug Reltecimod. It details clinical endpoints, statistical outcomes, adverse events, and the plan to submit an NDA to the FDA in Q3 2020. This content is characteristic of an Earnings Release (ER) or a detailed announcement of clinical trial results, which often precedes a formal regulatory filing or quarterly report. Since it focuses on the immediate release of key financial/clinical performance data and outlook, 'ER' (Earnings Release) is the most appropriate classification, as it functions as a major operational/financial update announcement. It is not a full Annual Report (10-K), a general Audit Report (AR), or a transcript (CT). It is a specific announcement of results, fitting the ER definition best.
2020-07-10 English
Arix Bioscience Plc - VelosBio completes $137 million Series B financing
Capital/Financing Update Classification · 1% confidence The document is a press release issued by Arix Bioscience plc announcing that its portfolio company, VelosBio, has completed a $137 million Series B financing round. This event directly relates to fundraising and capital structure changes for the portfolio company, which Arix is reporting on. The content focuses entirely on the successful completion of a financing round, which aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an official regulatory filing like a 10-K, an earnings release (ER), or a general regulatory announcement (RNS), but a specific corporate finance event announcement.
2020-07-08 English
Arix Bioscience Plc - Director/PDMR Shareholding, Issue of Ordinary Shares
Director's Dealing Classification · 1% confidence The document explicitly states it is a 'Director/PDMR Shareholding, Issue of Ordinary Shares' and contains detailed tables titled 'PDMR DEALING NOTIFICATION' reporting transactions by 'persons discharging managerial responsibilities' (PDMRs) like the Executive Chairman and COO. This directly corresponds to the definition of Director's Dealing (insider trades) which is classified as Code: DIRS. Although there is an 'Issue of Ordinary Shares' mentioned, the primary focus and structure of the filing is the disclosure of insider transactions.
2020-07-01 English
Arix Bioscience Plc - Aura presents updated AU-011 clinical data at ARVO 2020
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, reporting on clinical data updates from its portfolio company, Aura Biosciences, presented at the ARVO 2020 Annual Meeting. The text details clinical trial results (Phase 1b/2) for a drug candidate (AU-011), discusses future development plans (Phase 2 study, SC administration), and provides background on the disease and the technology. This content structure—announcing clinical/scientific updates, often referencing a conference presentation—is characteristic of an Investor Presentation (IP) or a detailed press release summarizing scientific progress. Since it contains substantial detail about the science, trial results, and future strategy, it goes beyond a simple Earnings Release (ER) or a brief Fund Factsheet (FS). It is not a formal regulatory filing like a 10-K or an IR. Given the focus on presenting scientific data and strategy to investors, 'Investor Presentation' (IP) is the most appropriate classification, even though it is delivered via a press release format, as it functions as a detailed investor update. *Self-Correction/Refinement:* While it is a press release, the content is a detailed summary of clinical data and strategy, which aligns closely with the purpose of an Investor Presentation (IP) or Management Discussion/Analysis (MDA). However, since it is explicitly announcing the presentation of data at a scientific conference (ARVO), it functions as a detailed scientific/clinical update aimed at investors. 'IP' covers detailed presentations on strategy and financials/pipeline progress. 'MDA' is usually management's explanation of *past* financial results. 'IP' fits best for pipeline updates presented at scientific forums.
2020-06-12 English
Arix Bioscience Plc - Imara presents positive interim Phase 2a data at EHA
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc announcing that its portfolio company, Imara Inc., presented positive interim Phase 2a clinical trial data for a drug (IMR-687) at the European Hematology Association (EHA) Annual Congress. This type of announcement, which details key results from a clinical trial presentation or study update, is typically classified as an Earnings Release (ER) if it pertains to financial results, or sometimes as a Regulatory Filing (RNS) if it's a general market update. However, since it is a specific announcement of clinical trial data presentation, it is most closely aligned with an Earnings Release (ER) which often includes operational/clinical milestones alongside financial highlights, or potentially an Investor Presentation (IP) if it were the presentation itself. Given the format is a PR Newswire release detailing results and future plans (Phase 2b initiation), it functions as an immediate disclosure of material information. Since it is not a full quarterly report (IR) or a formal presentation document (IP), and it is a direct announcement of results, ER is the most appropriate fit among the options for material operational/clinical updates released outside of a formal earnings call transcript (CT). It is not a Report Publication Announcement (RPA) because it contains the substance of the results, not just a notice that a report is available.
2020-06-12 English
Arix Bioscience Plc - Autolus AUTO1 and AUTO3 data at EHA
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc announcing data updates from its portfolio company, Autolus Therapeutics, presented at the European Hematology Association (EHA) Virtual Congress. The text contains key financial/clinical highlights, quotes from management and doctors, and details about an upcoming conference call/webcast to discuss the data. This structure—a brief announcement summarizing recent developments, often referencing a more detailed presentation or call—is characteristic of an Earnings Release (ER) or a general press announcement. Since it focuses on clinical data updates and company progress rather than formal quarterly financial statements (which would be IR or 10-K), and it is an initial announcement of results/progress, 'Earnings Release' (ER) is the most appropriate fit, even though the content is clinical/scientific rather than purely financial results. It is not a full transcript (CT), a formal annual report (10-K), or just a notice of a report publication (RPA), as it contains substantial content itself.
2020-06-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.